GET DAILY SIGNALSProMIS Neurosciences (PMN) Analyst Consensus Points to +334% Upside Potential
Key Takeaways
- The central $42 stock price target is the arithmetic mean of seven verified analyst price targets, rounded from roughly $42.
- Every collected target carries a Buy rating, but the range is extremely wide, from $18 (H.C. Wainwright) to $100 (Guggenheim), reflecting genuine disagreement over valuation.
- With the stock recently trading near $9.68, reaching $42 would require an upside of roughly 334%, a very large move.
- The bull case rests on lead candidate PMN310's differentiated profile in Alzheimer's disease, with topline Phase 1b data expected in the first quarter of 2027.
- The biggest risks are the company's pre-revenue status, a binary clinical readout, heavy dilution risk, and extreme share-price volatility.
- For the latest developments, explore PMN's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Price Targets and Consensus View
ProMIS Neurosciences Inc. (PMN) is a clinical-stage biotechnology company developing antibody therapies for Alzheimer's and other neurodegenerative diseases. It is followed by a relatively small group of analysts, all of whom currently rate the shares a Buy. Across seven verified, individually attributable targets collected from recent brokerage notes, the figures span from H.C. Wainwright's $18 (reiterated in October 2026) to Guggenheim's $100 (raised in August 2026). In between sit Roth MKM at $29, Chardan Capital at $33, Maxim Group at $35, and both Cantor Fitzgerald and Brookline Capital Markets at $40.
The arithmetic mean of these seven targets is approximately $42, which is the central target used here. The dispersion is unusually wide because analysts apply very different probability weightings to PMN310, the company's lead Alzheimer's candidate, and to the financing assumptions behind a pre-revenue developer. Guggenheim's triple-digit target is an outlier that pulls the average higher; excluding it, the remaining six targets average about $32.50. No single figure should be treated as a guarantee, and the wide range signals that even the bulls disagree sharply on magnitude. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
PMN shares have been highly volatile, trading in a 52-week range of roughly $6.27 to $27.40 after a one-for-25 reverse split in November 2025. The stock has recently changed hands around $9.68. A move to $42 would therefore represent an upside of about 334%, which must be described as a very large move even for a small-cap biotech. The likely path would be event-driven rather than gradual: investors are positioning ahead of the unblinded 12-month Phase 1b PRECISE-AD study of PMN310, with topline data expected in the first quarter of 2027. Positive efficacy and safety results could trigger a sharp re-rating, while a disappointing readout could unwind much of the current valuation.
What Could Support a Move Toward the Target
The core argument is PMN310's differentiated mechanism. The antibody targets toxic amyloid-beta oligomers, and early data have shown encouraging safety, pharmacokinetics, and biomarker effects, including low rates of ARIA (amyloid-related imaging abnormalities) and reductions in pTau-related measures. Analysts including Maxim Group's Jason McCarthy have cited a favorable risk-reward setup on this profile. The balance sheet is another factor: the company held over $53 million in cash and short-term investments as of its most recent quarter, and it announced a private investment in public equity (PIPE) financing of up to approximately $175 million. Analysts also note that ProMIS could follow the commercial playbook established by approved anti-amyloid therapies, potentially offering dosing convenience on top of efficacy and safety advantages.
What Could Prevent the Target From Being Reached
The obstacles are substantial. ProMIS generates no meaningful revenue and reports a net loss, meaning the entire valuation rests on unproven clinical outcomes. Alzheimer's drug development carries a high failure rate, and the Phase 1b readout in early 2027 is binary in nature. Financing activity, while supportive of the cash runway, dilutes existing shareholders and can pressure the stock. The shares also exhibit extreme volatility and low average trading volume relative to larger peers, and the 52-week range shows the stock has already traded well below and far above current levels. A negative readout, a safety signal, or further equity issuance could each materially disrupt the path to $42.
Technical Levels and Market Structure
PMN's post-split chart shows a long-term trading band between the 52-week low near $6.27 and the 52-week high near $27.40. The $27-$28 area represents a notable resistance zone, and a durable advance toward a $42 objective would first require the stock to reclaim and hold above its prior highs. The 50-day and 200-day moving averages have recently sat in the $11-$13 range, above the current price, suggesting the stock is trading below its intermediate-term trend. Psychological levels around $10 and $15 could act as near-term hurdles. These levels reflect market structure rather than a forecast of direction.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though firms do not always state this explicitly and the true horizon for a pre-revenue biotech often extends to a catalyst date. The single most important upcoming event is the topline Phase 1b PRECISE-AD readout expected in the first quarter of 2027. Investors should also watch quarterly results, with the next earnings report estimated for mid-November, updates on cash position and financing, any new biomarker or safety data on PMN310, and analyst revisions in the run-up to the readout. Regulatory milestones and broader sentiment toward the Alzheimer's sector can also move the shares.
AI Daily Buy/Sell Signals
In my own workflow, Tickeron's AI Daily Buy/Sell Signals have been helpful for tracking momentum shifts in names like PMN. The tool applies artificial intelligence to monitor thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on technical behavior and market conditions. For a volatile clinical-stage name, it offers a practical way to stay on top of changing trends alongside fundamental research.
Final Assessment
The question of whether PMN can reach $42 hinges almost entirely on PMN310's Phase 1b results. The $42 central target, derived from seven Buy-rated analyst estimates, implies a roughly 334% gain from recent levels and sits far above the stock's 52-week high, underscoring how much depends on a successful clinical outcome. The bull case rests on PMN310's differentiated safety and biomarker profile and a fortified cash position, while the bear case centers on a binary readout, ongoing losses, and dilution. With analyst targets ranging from $18 to $100, conviction is high but agreement on magnitude is not. The next meaningful signal will be the early-2027 data release, and until then the shares are likely to remain event-driven and highly volatile.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PMN's RSI Indicator recovers from oversold territory
The RSI Indicator for PMN moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 28 of the 31 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 64 cases where PMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on PMN as a result. In 76 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for PMN just turned positive on October 21, 2026. Looking at past instances where PMN's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
Following a +5.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 158 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.757) is normal, around the industry mean (2.974). P/E Ratio (-0.767) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement